The price of Allarity Therapeutics Inc. (NASDAQ:ALLR) shares last traded on Wall Street rose 25.77% to $0.28.
Based on available information, 1 analysts follow Allarity Therapeutics Inc. (NASDAQ:ALLR). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $8.00 and a low of $8.00, we find $8.00. Given the previous closing price of $0.22, this indicates a potential upside of 3536.36 percent. ALLR stock price is now -41.86% away from the 50-day moving average and -78.43% away from the 200-day moving average. The market capitalization of the company currently stands at $4.11M.
Among analysts, 1 rate the stock a hold while 0 rate it a buy. Brokers who have rated the stock have averaged $8.00 as their price target over the next twelve months.
A total of 13.38% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ALLR stock. A new stake in Allarity Therapeutics Inc. shares was purchased by BARCLAYS PLC during the first quarter worth $4,000. In total, there are 13 active investors with 1.70% ownership of the company’s stock.
A candlestick chart of Allarity Therapeutics Inc. (NASDAQ: ALLR) showed a price of $0.2340 on Thursday morning. During the past 12 months, Allarity Therapeutics Inc. has had a low of $0.22 and a high of $12.86. As of last week, the company has a debt-to-equity ratio of 0.79, a current ratio of 0.50, and a quick ratio of 0.50. The fifty day moving average price for ALLR is $0.4760 and a two-hundred day moving average price translates $1.2830 for the stock.
The latest earnings results from Allarity Therapeutics Inc. (NASDAQ: ALLR) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.52, missing analysts’ expectations of -$0.42 by -0.1. This compares to -$0.17 EPS in the same period last year. The company reported revenue of $4.56 million for the quarter, compared to $3.97 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 14.8 percent.
Allarity Therapeutics Inc.(ALLR) Company Profile
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.